Rare diseases
Investigational molecules
Locations
26 Rue D Ulm, 75005 Paris, France
Research activity is concentrated in breast cancer, with strong emphasis on triple-negative breast cancer (TNBC) across early-stage, high-risk, locally advanced, and metastatic settings. The portfolio also includes HER2-positive disease, ER-positive, HER2-negative metastatic disease, and molecularly defined subgroups such as GATA3-mutant and HER3-mutant breast cancer.
Interest extends to recurrence detection, biomarker-guided treatment selection, and post-treatment monitoring in advanced breast malignancies.
Institut Curie runs clinical trials in conditions such as Triple negative breast cancer, Retinoblastoma, Breast cancer metastatic, Breast cancer, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Study on Retinoblastoma Treatment Using Etoposide, Carboplatin, and Melphalan for Patients with Specific Eye Conditions
FranceStudy on 68Ga-FAPI-46 for Predicting Treatment Response in Early-Stage High-Risk Triple-Negative Breast Cancer Patients Undergoing Chemo-Immunotherapy
FranceStudy on Retinoblastoma Treatment: Evaluating the Effectiveness of Topotecan, Vincristine Sulfate, and Etoposide in Patients Eligible for Conservative Therapy
FranceStudy of Fluoroestradiol F-18 and Biomarkers for Women with ER-Positive HER2-Negative Metastatic Breast Cancer After CDK4/6 Inhibitor Therapy
FranceStudy on Early Detection of Triple-Negative Breast Cancer Relapse Using 68Ga-FAPI-46 for Patients at High Risk
FranceStudy of Tucatinib, Etoposide, and Trastuzumab for Patients with Metastatic HER2+ Breast Cancer After Progression or Capecitabine Toxicity
FranceStudy on 68Ga-FAPI-46 for Imaging in Patients with Non-Metastatic Pancreatic Cancer
FranceStudy of tucatinib and trastuzumab for patients with HER3-mutant and HER2-not amplified metastatic breast cancer
FranceStudy on Early Detection of Triple-Negative Breast Cancer Relapse Using [68Ga]Ga-FAPI-46 for Patients at High Risk
FranceStudy on Adjuvant Treatment for Unilateral Retinoblastoma with Vincristine Sulfate and Drug Combination in Patients After Primary Eye Removal
FranceStudy on the Effects and Safety of PLX038 for Patients with Advanced or Metastatic Triple-Negative Breast Cancer
FranceStudy of Milademetan and Fulvestrant for Patients with Advanced or Metastatic Breast Cancer with GATA3 Mutation, ER-Positive, HER2-Negative
FranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
